国家药监局批准注射用苏维西塔单抗上市

Core Viewpoint - The National Medical Products Administration has approved the marketing of Suweisita monoclonal antibody (brand name: Enzeshu) by Jiangsu Hengrui Medicine Co., Ltd., providing a new treatment option for patients with recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer after platinum-based therapy [1] Group 1 - The approved indication for Suweisita is in combination with paclitaxel, liposomal doxorubicin, or topotecan for adult patients who have received no more than one prior systemic therapy [1] - The launch of this product offers new therapeutic choices for relevant patients [1]